Ji Yun Lee1, Won Kee Lee2, Jae Yong Park3, Dong Sun Kim4. 1. Department of Anatomy and BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, 2-101 Dongin-dong, Jung-gu, Daegu, 702-422, Republic of Korea. 2. Department of Preventive Medicine, School of Medicine, Kyungpook National University, Daegu, 702-422, Republic of Korea. 3. Department of Internal Medicine, School of Medicine, Kyungpook National University, 2-101 Dongin-dong, Jung-gu, Daegu, 702-422, Republic of Korea. jaeyong@knu.ac.kr. 4. Department of Anatomy and BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, 2-101 Dongin-dong, Jung-gu, Daegu, 702-422, Republic of Korea. doskim@knu.ac.kr.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) poses a great threat to human health. DNA methylation abnormalities play a central role in the development and outcome of most human malignancies, providing potential biomarkers for diagnosis and prognosis. Iroquois homeobox 1 (IRX1) can act as a tumor suppressor or promoter depending on the tumor microenvironment, and its role in lung cancer is still controversial. OBJECTIVE: The purpose of this study was to investigate the biological role and prognostic value of IRX1 in NSCLC. METHODS: We examined the methylation status of IRX1 promoter in 146 tumors from patients with NSCLC using pyrosequencing and analyzed the association between methylation status and overall patient survival. RESULTS: A total of 37 cases (25.3%) showed IRX1 methylation-positive tumors when compared with matched normal tissues. No association between IRX1 expression level and methylation status was found in lung cancer cell lines. IRX1 methylation significantly correlated with smoking status and TP53 mutation. Patients with IRX1 methylation showed significantly longer survival than patients without methylation (log-rank P = 0.011). In a multivariate analysis of prognostic factors, IRX1 methylation in tumor samples was an independent prognostic factor (adjusted hazard ratio = 0.35, 95% confidence interval 0.17-0.73, P = 0.005). CONCLUSION: These results suggest that IRX1 promoter methylation may be a tumor-associated event and an independent predictor of survival advantage in patients with NSCLC. Further large-scale studies are needed to confirm these findings.
BACKGROUND:Non-small cell lung cancer (NSCLC) poses a great threat to human health. DNA methylation abnormalities play a central role in the development and outcome of most humanmalignancies, providing potential biomarkers for diagnosis and prognosis. Iroquois homeobox 1 (IRX1) can act as a tumor suppressor or promoter depending on the tumor microenvironment, and its role in lung cancer is still controversial. OBJECTIVE: The purpose of this study was to investigate the biological role and prognostic value of IRX1 in NSCLC. METHODS: We examined the methylation status of IRX1 promoter in 146 tumors from patients with NSCLC using pyrosequencing and analyzed the association between methylation status and overall patient survival. RESULTS: A total of 37 cases (25.3%) showed IRX1 methylation-positive tumors when compared with matched normal tissues. No association between IRX1 expression level and methylation status was found in lung cancer cell lines. IRX1 methylation significantly correlated with smoking status and TP53 mutation. Patients with IRX1 methylation showed significantly longer survival than patients without methylation (log-rank P = 0.011). In a multivariate analysis of prognostic factors, IRX1 methylation in tumor samples was an independent prognostic factor (adjusted hazard ratio = 0.35, 95% confidence interval 0.17-0.73, P = 0.005). CONCLUSION: These results suggest that IRX1 promoter methylation may be a tumor-associated event and an independent predictor of survival advantage in patients with NSCLC. Further large-scale studies are needed to confirm these findings.
Authors: Suhaida A Selamat; Brian S Chung; Luc Girard; Wei Zhang; Ying Zhang; Mihaela Campan; Kimberly D Siegmund; Michael N Koss; Jeffrey A Hagen; Wan L Lam; Stephen Lam; Adi F Gazdar; Ite A Laird-Offringa Journal: Genome Res Date: 2012-05-21 Impact factor: 9.043
Authors: Wenjie Yu; Xiao Li; Steven Eliason; Miguel Romero-Bustillos; Ryan J Ries; Huojun Cao; Brad A Amendt Journal: Dev Biol Date: 2017-07-23 Impact factor: 3.582
Authors: Miriam M Küster; Marc A Schneider; Antje M Richter; Sarah Richtmann; Hauke Winter; Mark Kriegsmann; Soni S Pullamsetti; Thorsten Stiewe; Rajkumar Savai; Thomas Muley; Reinhard H Dammann Journal: Cancers (Basel) Date: 2020-11-26 Impact factor: 6.639